PubMed Health⌕ Search

Biomedical subjects

Martin Wilkinson

Publications and source records attributed to Martin Wilkinson.

9 recordsLinked to original sources
PubMed2006

Using attached macroalgae to assess ecological status of British estuaries for the European Water Framework Directive.

The EC Water Framework Directive requires that ecological quality be assessed in transitional waters using the abundance and species composition of macroalgae. In estuaries, which form the majority of transitional waters, species composition is not a suitable measure. This arises from two features: (i) there is a continuous, natural change in species composition along the gradient of estuarine conditions which makes it difficult to know where within an estuary the species composition should be assessed, (ii) the inner estuarine macroalgal community of mat-forming species is very tolerant to both natural and anthropogenic stress and species poor which makes it insensitive to environmental variations in terms of species composition. An alternative feature is proposed based on the extent of upstream penetration of perennial fucoid algae. This proposal is founded on a series of case studies of the changes in fucoid limits, within a number of estuaries in the British Isles, consequent upon changes in pollution status over the last three decades. This also has to take into account variations of fucoid penetration owing to natural factors such as range of salinity variation and turbidity. The abundance criterion is taken to mean the absence of macroalgal blooms or "green tides", because general abundance of species is hard to quantify meaningfully in the upper estuarine mat-forming species and in the lower estuary is subject to great variation owing to the physical variability of estuary types.

Ecosystem↗
PubMed2006

The use of macroalgal species richness and composition on intertidal rocky seashores in the assessment of ecological quality under the European Water Framework Directive.

The EC Water Framework Directive (WFD) suggests using abundance and species composition of intertidal seaweed communities for ecological quality classification of rocky seashores. There are two difficulties with this. According to WFD all sensitive species should be present on a shore. There is no accepted list of sensitive seaweed species and those which may be sensitive in one location may not be so in another. Second, natural successions can result in very large abundance changes of common species, e.g. from almost completely fucoid-dominated shores to almost totally barnacle-dominated shores, without any change in ecological quality. Studies have shown that numerical species richness, not the list of actual species present, is broadly constant in the absence of disturbance. The ephemeral species, possibly the sensitive members of the community, change regularly in such a way as to conserve species richness. It is proposed that species richness on a defined length of shore be used as a criterion of ecological quality. A database of species found on over 300 shores in the British Isles, under strictly controlled sampling conditions, has given ranges of values of species richness to be expected and has allowed for variations in these values due to sub-habitat variability, wave exposure and turbidity to be factored in. A major problem in applying such a tool is the lack of expertise of many workers in critical identification of seaweed species. A reduced species list has been extracted from the database using species commonly present and identifiable with reasonable certainty. A numerical index of ecological quality is proposed based on scores for various aspects of the physical nature of the habitat combined with a score for species richness which may be based on the reduced species list. The scoring system also uses further aspects of community structure, such as ecological status groups and the proportions of rhodophyta, chlorophyta and opportunist species. For this system to be effective there has to be close control of the way in which sampling is carried out to ensure a uniform level of thoroughness.

Databases, Factual↗
PubMed2006

Defining and detecting undesirable disturbance in the context of marine eutrophication.

An understanding of undesirable disturbance to the balance of organisms is needed to diagnose marine eutrophication as defined by EU Directives and OSPAR. This review summarizes the findings of the UK Defra-funded Undesirable Disturbance Study Team, which concluded that 'an undesirable disturbance is a perturbation of a marine ecosystem that appreciably degrades the health or threatens the sustainable human use of that ecosystem'. A methodology is proposed for detecting disturbance of temperate salt-water communities dominated by phytoplanktonic or phytobenthic primary producers. It relies on monitoring indicators of ecosystem structure and vigour, which are components of health. Undesirable disturbance can be diagnosed by accumulating evidence of ecohydrodynamic type-specific changes in: (i) bulk indicators; (ii) frequency statistics; (iii) flux measurements; (iv) structural indicators; and (v) indicator species. These are exemplified by (i) chlorophyll, transparency, dissolved oxygen, and opportunistic seaweed cover; (ii) HABs frequency; (iii) primary production; (iv) benthic and planktonic 'trophic indices'; (v) seagrasses and Nephrops norvegicus. Ecological Quality Objectives are proposed for some of these. Linking the diagnosis to eutrophication requires correlation of changes with nutrient enrichment. The methodology, which requires the development of a plankton community index and emphasizes the importance of primary production as an indicator of vigour, can be harmonized with the EU Water Framework Directive and OSPAR's Strategy to Combat Eutrophication.

Chlorophyll↗
PubMed2006

Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.

BACKGROUND: Early virological response to antiretroviral therapy is predictive of long-term treatment outcome in therapy-naive patients. In treatment-experienced patients, such correlations are less well defined, because initial responses may be less pronounced and transient because of accumulated cross-resistance to prior therapies. Our objectives were to explore how the virological and immunological status of treatment-experienced patients at an early time point (week 12) during enfuvirtide-based therapy predicted their responses at weeks 24, 48, and 96 in the T-20 versus Optimized Regimen Only (TORO) trials. METHODS: Post hoc, modified, on-treatment and intent-to-treat analyses were performed to determine whether the relationship between virological and immunological outcomes at weeks 24, 48, and 96 were predicted by the patients' week-12 responses to therapy. RESULTS: Using a modified on-treatment analysis for patients who, by week 12, achieved a decrease in their HIV-1 RNA load of > or =1 log10 copies/mL, 39.2% (95% CI, 33.6%-44.8%) and 59.5% (95% CI, 53.8%-65.1%) achieved a viral load of <50 copies/mL or <400 copies/mL at week 96, respectively, compared with 1.3% (95% CI, 0%-3.8%) and 2.6% (95% CI, 0%-6.1%) of patients, respectively, who did not achieve an early virological response. Using the same modified on-treatment analysis method for patients who, at week 12, achieved a CD4 cell count increase of > or =50 cells/mm3, 87.2% (95% CI, 82.6-91.8) maintained or improved this response through week 96, compared with 56.6% (95% CI, 47.5-65.8) of patients who did not achieve this early categorical immunological response. CONCLUSION: Enfuvirtide-based treatment regimens are associated with a rapid and durable response. Week-12 virological and immunological responses to treatment with enfuvirtide are predictive of subsequent outcomes in triple-class treatment-experienced patients.

Clinical Trials, Phase III as Topic↗
PubMed2005

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.

BACKGROUND: The T-20 Versus Optimized Background Regimen Only (TORO) 1 and TORO 2 clinical trials are open-label, controlled, parallel-group, phase 3 studies comparing enfuvirtide plus an optimized background (OB) of antiretrovirals (n = 661) with OB alone (n = 334) in treatment-experienced HIV-1-infected patients. METHODS: The primary objective at week 48 was to investigate durability of efficacy, as measured by the percentage of patients maintaining their week 24 response or improving. Efficacy analyses used the intent-to-treat population. RESULTS: A total of 73.7% of patients randomized to the enfuvirtide group remained on treatment through week 48 versus 21.3% originally randomized to the control group. At week 48, a higher proportion of week 24 responders maintained their response or were new responders in the enfuvirtide group than in the control group in each responder category: HIV-1 RNA level > or =1.0 log(10) change from baseline, <400 copies/mL and <50 copies/mL (37.4%, 30.4%, and 18.3% in the enfuvirtide group vs. 17.1%, 12.0%, and 7.8% in the control group, respectively; P < 0.0001 for all comparisons). CD4 cell count increases from baseline were twice as great in the enfuvirtide group as in the control group. CONCLUSION: These data demonstrate durable efficacy of enfuvirtide plus OB over 48 weeks.

Adolescent↗
PubMed2005

Payments to research subjects.

There is strong opposition in bioethics to paying research subjects. This paper, building on earlier work, gives arguments on behalf of the permissibility of payment. It develops an analogy between payment to research subjects and payment and regulation in the labour market. Few seriously oppose payment in the labour market, and the reasons to allow payment carry over to payment to research subjects. The paper then considers and rejects an alleged disanalogy, that research is special in that it involves subjects' bodies. At greater length, it assesses the argument from the gift relationship: that the value of giving is good reason not to extend market norms into research. This argument has some force in pointing out the unattractiveness of some market motivations, but those who offer it usually overlook the coordination advantages of the market. Still, the gift relationship argument against payment has something going for it, which is more than can be said for virtually all the other major anti-payment arguments.

Employment↗
PubMed1999

Inducements revisited.

The paper defends the permissibility of paying inducements to research subjects against objections not covered in an earlier paper in Bioethics. The objections are that inducements would cause inequity, crowd out research, and undesirably commercialize the researcher-subject relationship. The paper shows how these objections presuppose implausible factual and/or normative claims. The final position reached is a qualified defence of freedom of contract which not only supports the permissibility of inducements but also offers guidance to ethics committees in dealing with practical problems that might arise if inducements are offered.

Altruism↗
PubMed1997

Inducement in research.

Opposition to inducement payments for research subjects is an international orthodoxy amongst writers of ethics committee guidelines. We offer an argument in favour of these payments. We also critically evaluate the best arguments we can find or devise against such payments, and except in one very limited range of circumstances, we find these unconvincing.

Coercion↗